Welcome to our dedicated page for Atrium Therapeutics SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avidity Biosciences, Inc. (Nasdaq: RNA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Avidity describes its Antibody Oligonucleotide Conjugates (AOCs™) platform, its late-stage neuromuscular programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), and its broader pipeline in precision cardiology and immunology.
Current reports on Form 8-K are especially important for tracking material events at Avidity. Recent 8-K filings have covered topics such as the definitive merger agreement with Novartis AG, the related Separation and Distribution Agreement for the spin-off or sale of early-stage precision cardiology programs into SpinCo, positive clinical data from the EXPLORE44® and EXPLORE44-OLE™ trials of delpacibart zotadirsen (del-zota) in DMD44, and regulatory milestones including Breakthrough Therapy designation and updated BLA submission timing for del-zota. Other 8-Ks detail public equity offerings, amendments to equity incentive plans, and executive compensation arrangements in connection with the proposed merger.
Investors and analysts can also use Avidity’s SEC filings to confirm listing information for its common stock (trading under the symbol RNA on The Nasdaq Global Market), review descriptions of SpinCo and the planned spin-off structure, and understand the conditions, termination provisions and timing expectations associated with the Novartis transaction. These filings often reference additional documents such as proxy statements, registration statements for SpinCo and financial reports that further explain Avidity’s operations, risk factors and capital structure.
On Stock Titan, Avidity’s filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as clinical program updates, collaboration milestones, merger terms and changes in executive compensation. Real-time updates from EDGAR, combined with structured access to Forms 8-K and other filings, make this page a practical starting point for reviewing Avidity’s regulatory history, including material events related to its AOC platform, neuromuscular pipeline and the proposed acquisition by Novartis.
BlackRock, Inc. files a Schedule 13G reporting beneficial ownership of 892,387 shares of Atrium Therapeutics, Inc. common stock, representing 5.2% of the class as reported. The filing lists sole voting power for 880,175 shares and sole dispositive power for 892,387 shares. The cover date shown is 03/31/2026 and the Schedule is signed on 04/27/2026. The filing states the holdings reflect securities held by certain Reporting Business Units of BlackRock and notes various persons may have rights to dividends or sale proceeds.
Atrium Therapeutics, Inc. granted equity awards to executive Stephanie Kenney on April 20, 2026. She received 30,000 shares of common stock as restricted stock units, bringing her direct common stock holdings to 35,460 shares after the award.
Kenney was also granted stock options for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036. Both the RSUs and options vest over multiple years starting March 20, 2027, subject to her continued service with the company.
Atrium Therapeutics’ Chief Medical Officer Steven George Hughes reported new equity compensation consisting of restricted stock units and stock options. He received 30,000 RSUs, each representing one future share of common stock, bringing his directly held common shares to 73,097 after the award.
The RSUs vest over four years, with 25% vesting on March 20, 2027 and the rest in three yearly installments, contingent on continued service. He was also granted options for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036.
These options vest with 25% becoming exercisable on March 20, 2027 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter, also subject to continued service.
Atrium Therapeutics, Inc. reported that its Chief Financial Officer, Brendan R. Winslow, received equity compensation consisting of restricted stock units and stock options. He was granted 30,000 shares of Common Stock as an award, bringing his direct holdings to 43,601 shares after the transaction.
He was also granted 60,000 stock options to buy Common Stock at an exercise price of $14.30 per share, expiring on April 20, 2036. According to the award terms, 25% of the RSUs vest on March 20, 2027, with the remainder vesting in three yearly installments. For the options, 25% of the underlying shares vest on March 20, 2027, with the remaining shares vesting in 36 substantially equal monthly installments. These are compensation-related grants, not open-market purchases.
Atrium Therapeutics, Inc. director and officer Kathleen P. Gallagher reported receiving equity awards as part of her compensation. She was granted 102,500 shares of common stock in the form of restricted stock units, with each unit representing one future share of common stock, subject to vesting.
Gallagher was also granted a stock option for 205,000 shares of common stock at an exercise price of $14.30 per share. Twenty-five percent of both the RSUs and the option vest on March 20, 2027, with the remaining portions vesting over subsequent years, contingent on her continued service. After these grants, she directly owns 131,361 shares of common stock and holds the full 205,000-share stock option.
Atrium Therapeutics, Inc. reported that Chief Strategy Officer Rocio Martin Hoyos received equity-based compensation. She was granted 30,000 shares of common stock in the form of restricted stock units and now holds 46,660 common shares directly after this award.
She was also granted a stock option for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036. Both the RSUs and options vest over several years starting March 20, 2027, contingent on continued service with the company.
Atrium Therapeutics, Inc. Chief Scientific Officer Husam Younis reported equity compensation awards. He received 30,000 shares of common stock as restricted stock units, which vest 25% on March 20, 2027 and then in three yearly installments, contingent on continued service. He was also granted options for 60,000 shares of common stock at an exercise price of $14.30 per share, vesting 25% on March 20, 2027 and the balance in 36 equal monthly installments through April 20, 2036. Following the stock award, his direct common stock holdings total 52,657 shares.
T. Rowe Price Associates, Inc. reported beneficial ownership of 1,553,210 shares of Atrium Therapeutics common stock, representing 10.0% of the class as of 03/31/2026. The filing lists sole voting power of 1,552,984 shares and sole dispositive power of 1,553,210 shares. The Schedule 13G is signed by a T. Rowe Price officer on 04/08/2026.
Avidity Biosciences, Inc. reported that Chief Human Resources Officer Teresa McCarthy disposed of company equity in connection with the previously agreed merger with Novartis AG. The filing shows an issuer disposition of multiple stock option awards and 165,296 shares of Common Stock, including shares underlying previously reported restricted stock units.
According to the merger terms, each reported share of Common Stock was converted into the cash merger consideration of $72.00 per share. The stock options were canceled in exchange for a cash payment equal to the excess of the $72.00 merger price over their exercise price, indicating these were cash-settled, merger-related transactions rather than open-market trades.
Avidity Biosciences director Tamar Thompson reported disposing of all her Avidity equity in connection with the company’s merger with Novartis. Footnotes state that her common stock, including shares underlying previously reported restricted stock units, was transferred to the issuer under the merger agreement, and her stock options were cancelled in exchange for cash equal to the merger consideration of $72.00 per share minus each option’s exercise price. Following these issuer dispositions on February 27, 2026, her reported holdings of both common stock and options are shown as zero.